Progyny Inc [PGNY] stock prices are up 1.34% to $37.05 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PGNY shares have gain 4.66% over the last week, with a monthly amount drifted -8.06%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 18, March 2024, Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum. In a post published today on Yahoo Finance, Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 1:30 P.M. Eastern Time.
From an analyst’s perspective:
Progyny Inc [NASDAQ: PGNY] stock has seen the most recent analyst activity on February 26, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $49. Previously, Barclays started tracking the stock with Overweight rating on January 03, 2024, and set its price target to $48. On September 27, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $46 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $50 on May 22, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $44 as its price target on April 21, 2023. SVB Leerink downgraded its rating to Mkt Perform for this stock on January 05, 2023, but kept the price target unchanged to $34. In a note dated September 16, 2022, KeyBanc Capital Markets initiated an Overweight rating and provided a target price of $55 on this stock.
The stock price of Progyny Inc [PGNY] has been fluctuating between $29.44 and $44.95 over the past year. Progyny Inc [NASDAQ: PGNY] shares were valued at $37.05 at the most recent close of the market.
Analyzing the PGNY fundamentals
The Progyny Inc [NASDAQ:PGNY] reported sales of 1.09B for trailing twelve months, representing a surge of 25.95%. Gross Profit Margin for this corporation currently stands at 0.22% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.13 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.51 points at the first support level, and at 35.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.67, and for the 2nd resistance point, it is at 38.29.
Progyny Inc [PGNY] reported earnings per share of $0.13 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.11/share, meaning a difference of $0.02 and a surprise factor of 18.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.16 per share as compared to estimates of $0.12 per share, a difference of $0.04 representing a surprise of 33.30%.
Ratios To Look Out For
It’s worth pointing out that Progyny Inc [NASDAQ:PGNY]’s Current Ratio is 3.44. Also, the Quick Ratio is 3.44, while the Cash Ratio stands at 0.52. Considering the valuation of this stock, the price to sales ratio is 3.28, the price to book ratio is 6.41 and price to earnings (TTM) ratio is 60.07.
Transactions by insiders
Recent insider trading involved Payson Norman, Director, that happened on Nov 23 ’24 when 200.0 shares were sold. CHIEF FINANCIAL OFFICER, Livingston Mark S. completed a deal on Mar 01 ’24 to sell 12610.0 shares. Meanwhile, PRESIDENT Sturmer Michael E sold 11009.0 shares on Mar 01 ’24.
